Global Antisense & RNAi Therapeutics Market, By Technology (RNA Interference and Antisense RNA), By Application (Genetic Disease, Cancer, Infectious Disease, Neurodegenerative Disorders, Cardio Metabolic & Renal Disorders, Ocular Disorders, Respiratory Disorders, Skin Disorders and Others), By Route of Administration (Intravenous Injections, Intrathecal Injections, Subcutaneous Injections and Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)
Antisense & RNAi therapeutics refer to a class of drugs that use naturally occurring processes to target and inhibit the expression of specific genes. They work by binding to mRNA or genomic DNA with high specificity. This inhibits the expression of disease-associated proteins. The antisense & RNAi therapeutics market is growing substantially due to its potential to treat various conditions with high specificity and few side effects. These include viral infections, cancers, genetic disorders, and others. The market is witnessing significant investments in R&D as many drug candidates are progressing through clinical trials. The development of novel drug delivery techniques is also extending the potential of antisense & RNAi therapeutics to target previously undruggable diseases.
Market Dynamics:
Antisense and RNAi therapeutics are novel nucleic acid-based therapeutics designed to inhibit the expression of disease-causing genes. They work by binding to mRNA transcripts, preventing translation, or inducing mRNA degradation. This offers promise for treating various genetic disorders, cancers, and viral infections by selectively silencing unwanted genes. The technology utilizes short synthetic strands of nucleic acids such as DNA, RNA, or modified versions that are complementary to the target mRNA. The global antisense & RNAi therapeutics market is driven by the growing prevalence of various cancers, genetic disorders, and infectious diseases worldwide. RNA-targeting drugs have demonstrated safety and efficacy in clinical trials for various conditions, boosting market growth. Moreover, continuous advancements in nucleotide drug delivery systems, such as nanoparticles, have enhanced intracellular uptake of these therapeutics, expanding their clinical applications. However, high research and development costs associated with drug development and potential off-target effects are some of the challenges faced by market players. Meanwhile, the upcoming patent expiries of major brands will provide opportunities for generic versions. In addition, the development of novel RNAi drug platforms targeting chronic diseases will further stimulate market expansion.
Key features of the study:
This report provides in-depth analysis of the global antisense & RNAi therapeutics market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global antisense & RNAi therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Benitec Biopharma Inc., Silence Therapeutics, Ionis Pharmaceuticals, Inc, Bio-Path Holdings Inc., Percheron Therapeutics Limited, GSK plc, Olix Pharmaceuticals, Inc., Sanofi, Alnylam Pharmaceuticals, Inc. and Arbutus Biopharma.
These companies are involved in the research, development, manufacturing, and distribution of controlled substances
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global antisense & RNAi therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antisense & RNAi therapeutics market
Detailed Segmentation:
By Technology:
RNA Interference
Antisense RNA
By Application:
Genetic Disease
Cancer
Infectious Disease
Neurodegenerative Disorders
Cardio Metabolic & Renal Disorders
Ocular Disorders
Respiratory Disorders
Skin Disorders
Others
By Route of Administration:
Intravenous Injections
Intrathecal Injections
Subcutaneous Injections
Others
By Region:
North America
Europe
Asia Pacific
Latin America
Middle East
Africa
Top companies in Antisense & RNAi Therapeutics Market
Benitec Biopharma Inc.
Silence Therapeutics
Ionis Pharmaceuticals, Inc
Bio-Path Holdings Inc.
Percheron Therapeutics Limited
GSK plc
Olix Pharmaceuticals, Inc.
Sanofi
Alnylam Pharmaceuticals, Inc.
Arbutus Biopharma
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Technology
Market Snippet, By Application
Market Snippet, By Route of Administration
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis